This year, an overwhelming number of NEALS members were invited to participate in the meeting; the membership gave multiple plenary talks, served as session chairs, participated in platform presentations, and presented abstract posters over the week-long program.
More information about Radicava (Edaravone) and when it will be available in the US.
Today, the FDA approved the drug Edaravone for the treatment of ALS. NEALS is thrilled to now have another medication for our patients. For more information on how to access Edaravone, contact the staff and physicians at your ALS Clinic.
Nominations and self-nominations are now being accepted for the 2017 Clinical Research Learning Institute (CRLI)! Patients, caregivers and patient-caregiver pairs are encouraged to apply.
NEALS Research Ambassadors, Stephen Winthrop and Pete Frates, were recently interviewed by WCVB, the Boston ABC affiliate, about their commitment to clinical trials and the fight against ALS.
Madeline Kennedy describes the benefits of a multidisciplinary care approach for people living with ALS.
Please join us on March 23rd for a webinar discussion on cannabinoid use in ALS led by Drs. Mark Ware and Angela Genge from the Montreal Neurological Institute and Hospital. Dr. Ware will discuss the mechanism of action of cannabinoids, while Dr. Genge will discuss their use in symptom management, and possible effect on disease course.
Barrow Neurological Institute is seeking individuals to participate in a remote research study called ALS AT HOME, enrolling under the direction of Dr. Jeremy Shefner.
NEALS is pleased to announce a full day training session for NEALS investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
Neuraltus Pharmaceuticals, Inc., is currently enrolling up to 120 individuals with ALS and evidence of systemic inflammation in a second Phase 2 study of its investigational treatment NP001, an immune system regulator.
